Browsing by Author "Singh, Narendra Kumar"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Publication Ayurvedic strategy to achieve sustainable development goal 3: Management of cancer (Arbuda)(Nova Science Publishers, Inc., 2022) Singh, Anupriya; Upadhyay, Anjali; Singh, Jyoti; Singh, Ambrish Kumar; Singh Gautam, Dev Nath; Singh, Narendra KumarCancer is the second leading cause of morbidity and mortality as well as growing health problems worldwide. Effective drugs and therapies are available for different kinds of cancer also having side effects; hence people seek relatively safer as well as cost-effective alternative and complementary medicines for the treatment of cancer. The objective of the present chapter is to provide Ayurvedic concept-based evidence for the treatment and management of cancer to the academician and researcher who garners interest in cancer. The present study provides comprehensive information about Arbuda (cancer) and its probable remedy through Ayurveda and fulfilling the Sustainable Development Goals (SDGs) that is SDG 3. Arbuda develops due to Mithya Ahar (unhealthy diet) and Mithya Vihar (unhealthy lifestyle) leading to imbalance in Vatadi Doshas (regulatory functional factors of the body) which leads to vitiation of Dhatus (major structural components of the body). Vitiated Dhatus results in the formation of muscular swelling anywhere in the body with the appearance of large, circular, immobile, less painful, slowly growing and deep-seated swelling such a clinical entity termed as Arbuda. Symptomatically, Arbuda may have a resemblance with clinical entities such as cancer. However, the exact pathogenesis of cancer does not match these two conditions, but still, it may be possibly correlated up to a certain extent. The involvement of one or two Doshas (Vata, Pitta and Kapha), produce benign neoplasm which is harmless but the association of all three Doshas (Sannipataja/Tridoshaja) produces malignant neoplasm, which is harmful. The term Dviarbuda (metastasis) and Adhyarbuda (recurrence) are considered Asadhya (incurable) and these two terminologies may be correlated to the metastatic growth of cancer cells. Management of Arbuda includes all those plants having Laghu, Ruksha and Tikshna Guna may possess Lekhana and Kaphashamak action. � 2022 Nova Science Publishers, Inc..Publication Pongamol from the seeds of Tephrosia purpurea exert anti-cancer activity against cervical cancer cell line(National Institute of Science Communication and Policy Research, 2023) Kumari, Snehal; Chaudhary, Neha; Priya, Khushbu; Rai, Geeta; Gautam, Dev Nath Singh; Singh, Narendra KumarTephrosia purpurea belongs to the family Fabaceae, is used for the treatment of inflammation, diabetes, cancer, chronic fever, boils, gingivitis etc. In the present study, three compounds (TP-1, TP-3 and TP-5) were isolated from ethyl acetate extract of the seeds of T. purpurea (EETP). Quantity of TP-3 (6.05%) in EETP was determined by HPLC. In-vitro anti-cancer activity of EETP and isolated compound TP-3 on SiHa cells as well as PBMCs (peripheral blood mononuclear cells) were evaluated by MTT (3-(4,5-di methyl thiazol-2-yl)-2,5-di phenyl tetrazolium bromide) assay. On the basis of spectroscopic analysis and physical properties, structure of isolated compounds TP-1, TP-3 and TP-5 were characterized as teclenone, pongamol and ?-sitosterol respectively. Isolated compound TP-3 showed cytotoxicity against SiHa cells with the IC50 33.06 �gmL-1. TP-3 showed significant cytotoxicity at the concentration range from 20-50 �gmL-1 as compared to control. Maximum cytotoxicity (72.75%) was observed at the concentration of 50 �gmL-1. TP-3 showed non-significant cytotoxicity against PBMCs cells at all the concentrations except at 50 �gmL-1 (cytotoxicity 24.19%). EETP showed significant cytotoxicity (IC50 value 113.63 �gmL-1) against SiHa cells at the concentration range from 75-150 �gmL-1 as compared to control. Maximum cytotoxicity (75.34%) was observed at the concentration of 150 �gmL-1. � 2023, National Institute of Science Communication and Policy Research. All rights reserved.